3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
13
Observational
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Carcinoma, Hepatocellular
11
Stomach Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Myositis
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Vascular Complications
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Sarcopenia
1
Recurrence
1
Rectal Neoplasms
1
Plaque, Atherosclerotic
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Metastatic Colorectal Adenocarcinoma
1
Melanoma
1
Lupus Erythematosus, Systemic
1
Lung Diseases, Interstitial
1
Liver Neoplasms
1
Influenza, Human
1
Immune-Related Adverse Events
1
Hypersensitivity
1
Interventions
Blood Specimen Collection
14
Nivolumab
13
Ipilimumab
12
pembrolizumab
11
trametinib
9
Surveys and Questionnaires
9
Gene Expression Profiling
9
dabrafenib
8
Biopsy
6
Specimen Handling
5
Immunotherapy
5
Immunohistochemistry
5
Amplified Fragment Length Polymorphism Analysis
4
encorafenib
3
binimetinib
3
atezolizumab
3
Restraint, Physical
3
Quality of Life
3
Polymerase Chain Reaction
3
Introns
3
Flow Cytometry
3
Drug Therapy
3
Data Collection
3
tremelimumab
2
pimonidazole
2
cobimetinib
2
aldesleukin
2
Watchful Waiting
2
Vemurafenib
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Melanoma
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05037825
2022-04-27
PARADIGM
VastBiome
Recruiting
800 enrolled